Aesica adds development capability with new purpose built facility

Aesica Pharmaceuticals, the global pharmaceutical contract development and manufacturing organisation (CDMO), has recently doubled its development capacity – manufacturing multiple drug products up to Phase III clinical trials at Queenborough.

With the addition of new capabilities in a dedicated Development Centre, Aesica can develop and manufacture a customer product from early formulation development through to clinical manufacture and into commercialisation – covering all aspects of the product life cycleand providing a seamless end-to-end service for the customer.

The company’s high potent and controlled drugs service offering has been significantly expanded at Queenborough as a result of the new Development Centre. Whilst previously Aesica only provided commercial scale manufacturing capabilities for these drug classifications, it now offers full formulation and development capabilities in these specialist fields. The site handles high potent drugs for any active up to SafeBridge Category 3, together with controlled drugs, with licenses for both Schedules 2 to 4. Moreover, the facility is therefore experienced in handling drugs that are both highly potent and at the same time controlled.

Ian Muir, Managing Director of Aesica Pharmaceuticals commented; “In response to growing customer demand, and as part of our on-going strategy to meet the needs of the market to simplify the supply chain with reliable, highly efficient, single source solutions, our high capacity Development Centre – which doubles our development capacity, combined with our commercial manufacturing capabilities – provides a complete service offering for formulation, development and product manufacturing for multiple customers.”

He continued: ‘High potency is a key contract services market, with strong growth potential, requiring a mix of highly specialised and advanced technological skills and capabilities. We have set these resources in place and have taken the strategic initiative to combine them with full clinical and commercial scale manufacturing capacity in this highly complex field – further enhancing our offering to customers.”